Studies have hypothesized a potential role of the interleukin (IL)-23/17 axis in coronavirus disease 2019 (COVID-19). However, to date, levels of IL-23 and 17 have not been compared between critically ill COVID-19 patients and critically ill non-COVID-19 patients. IL-23 and 17 were measured on admission to the intensive care unit (ICU) in critically ill COVID-19 ( N = 38) and critically ill non-COVID-19 ( N = 34) patients with an equal critical illness severity. Critically ill non-COVID-19 patients did not have sepsis or septic shock on ICU admission. None of the enrolled patients had previously received corticosteroids. In our study, circulating IL-17 levels were higher in the COVID-19 patients. More specifically, critically ill COVID-19 patients had levels of 0.78 (0.05–1.8) pg/mL compared to 0.11 (0.05–0.9) pg/mL in the critically ill non-COVID-19 patients ( p = 0.04). In contrast, IL-23 levels were comparable between groups. A group of patients hospitalized in the specialized COVID-19 clinic ( N = 16) was also used to evaluate IL-17 and IL-23 levels with respect to COVID-19 severity. Non-critically ill COVID-19 patients had undetectable levels of both cytokines. Our results support the notion of inhibiting IL-17 in critical COVID-19 infection.
【저자키워드】 COVID-19, Critically ill, IL-17, IL-23, personalized treatment, 【초록키워드】 coronavirus disease, Corticosteroids, Cytokines, intensive care, COVID-19 severity, Sepsis, ICU, COVID-19 infection, Patient, ICU admission, Septic shock, Admission, Critical, COVID-19 patients, COVID-19 patient, Illness severity, Support, Non-COVID-19, Non-COVID-19 patients, circulating, enrolled, comparable, groups, inhibiting, were measured, non-COVID-19 patient, patients hospitalized, undetectable, used to evaluate, 【제목키워드】 axis, role, Evaluating, Ill,